New publication 📝 Phase II results published in Leukemia & Lymphoma provide new insights for #RRMM, see: loom.ly/BlF_VT4

An MRD analysis from the PERSEUS trial presented at #EHA2024 found that D-VRd plus D-R maintenance continued to improve MRD negativity rates vs VRd + R in transplant-eligible patients with #NDMM 📝 More news: multiplemyelomahub.com #Myeloma #MedNews #MedEd

🚨 NEWS 🚨 The U.S. FDA has issued a complete response letter for the biologics license application for linvoseltamab, an investigational BCMA-directed bispecific antibody, for the treatment of relapsed/refractory #MultipleMyeloma, with progression after 3 prior therapies. Read

A new study published in Leukemia & Lymphoma found that the KPd regimen was associated with an ORR of 57.7% in patients with early RRMM who were refractory to lenalidomide 📝 More news: multiplemyelomahub.com #RRMM #MedNews #MedEd

🚨 NEWS 🚨 China NMPA grants approval to ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, for the treatment of patients with RRMM after ≥3 prior lines of therapy, including a PI and an IMiD. The decision is based on the data from the phase II CARTIFAN-1 trial.

New publication 📝 Results from Cohort C of MajesTEC-1 trial published in Blood Journal provide new insights for anti-BCMA exposed relapsed/refractory #multiplemyeloma, see: loom.ly/iwy8KDE #mmsm #myeloma

During #EHA2024, Sagar Lonial MD, Emory University, Atlanta, US, hosted a roundtable discussion based on #CARTtherapy and #bispecific antibodies in relapsed/refractory #MultipleMyeloma. loom.ly/BTv7IoA #lymsm #mmsm #CARTtherapy European Hematology Association ESH (Haematology)

A new study published in Blood Journal found the safety and efficacy of teclistamab was similar in patients with and without prior exposure to anti-BCMA therapy 📝 More news: loom.ly/WDsgsjI #myeloma #MedNews #MedEd

📢 Only 1 day to go!  The #MultipleMyeloma Hub will be covering #SOHO2024. 📅 Sep 4–7   📍 Houston, US, and online We’ll be providing live social media coverage. Keep an eye on our socials to see the latest updates! #mmsm Society of Hematologic Oncology (SOHO)

CONGRESS | #SOHO2024 Ajay Nooka, MD, MPH Emory School of Medicine discusses whether quadruplet regimens should be used for all patients with NDMM; concluding that upfront quad therapies are the standard of care for both transplant eligible and ineligible patients. #mmsm #myeloma

CONGRESS | #SOHO2024 Krina Patel MD Anderson Cancer Center debates for the use of CAR T in the early relapsed setting, concluding that there is a place for CAR T in both the early and late relapsed setting, with latest data showing evidence for unprecedented high efficacy rates in both

CONGRESS | #SOHO2024 Saad Usmani Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Memorial Sloan Kettering Cancer Center argues that there are too many unknowns for CAR T-cell therapies in earlier lines to apply this to all patients, furthermore there are novel therapies being investigated for early relapsed setting that may influence

CONGRESS | #SOHO2024 Suzanne Lentzsch @Slentzsch Herbert Irving Comprehensive Cancer Center discusses the definition and treatment of HR-NDMM and functional HR #MultipleMyeloma. High-remission rates are possible but duration is often short, highlighting an unmet need amongst these patients. #mmsm #myeloma

CONGRESS | #SOHO2024 Meletios Dimopoulos Thanos Dimopoulos presents on the treatment options for first relapse in #MultipleMyeloma; sharing data from the latest clinical trials of approved and investigational agents. #mmsm #myeloma

CONGRESS | #SOHO2024 Dr. Amrita Krishnan City of Hope | Orange County discusses sequencing and resistance associated with T-cell engagers in #MultipleMyeloma. Krishnan suggests methods to effectively sequence T-cell engagers using different targets and modalities, with potential for future

CONGRESS | #SOHO2024 Meletios Dimopoulos Thanos Dimopoulos presents an analysis of MRD from the phase III PERSEUS study of D-VRd for transplant-eligible NDMM. Sustained MRD-neg rates were improved with D-VRd across all subgroups and at >12 months were approximately double compared to

CONGRESS | #SOHO2024 | POSTER Krina Patel MD Anderson Cancer Center shares results from a subanalysis of data from Black patients enrolled in the KarMMa-3 study. ORR 89%, sCR 50%, median DoR 17.5 mo, median PFS 20.3 mo, 9-mo PFS 77%, CRS 82%, iiNT 12%. The clinical benefit of ide-cel

CONGRESS | #SOHO2024 | POSTER Sagar Lonial MD Winship Cancer Institute of Emory University shares data from the CC-220-MM-001 trial of IberVd in transplant-ineligible NDMM. ORR 100%, ≥CR 56.25%, MRD-neg 43%, infections 76.5%, Grade 3/4 infections 35.3%, neutropenia 35.3%, Grade 3/4 neutropenia 23.5%. #mmsm

🔎 Gain insight into the next wave of immune-based therapies in #Lymphoma and #MultipleMyeloma. Watch the session from #EHA2024, led by Krina Patel, MD Anderson Cancer Center, Houston, US: loom.ly/KMNCr-A #lymsm #mmsm #CARTtherapy European Hematology Association ESH (Haematology)

New publication 📝 Real-world data published in Blood Advances provide new insights for older patients with relapsed/refractory #MultipleMyeloma, see: loom.ly/IfUE--c #mmsm #myeloma